Amonafide : An active agent in the treatment of previously <font color="blue">untreated_1</font> <font color="blue">advanced_1</font> <font color="blue">breast_1</font> <font color="blue">cancer_1</font> <font color="blue">--_1</font> a cancer and leukemia group B study ( CALGB 8642 ) . 
<br>
<br> Amonafide is a new imide derivative of naphthalic acid . The drug had demonstrated <font color="blue">significant_1</font> <font color="blue">activity_1</font> <font color="blue">in_1</font> <font color="blue">preclinical_1</font> <font color="blue">studies_1</font> <font color="blue">and_1</font> <font color="blue">some_1</font> <font color="blue">activity_1</font> <font color="blue">in_1</font> <font color="blue">Phase_1</font> <font color="blue">I_1</font> <font color="blue">trials_1</font> <font color="blue">._1</font> The drug is extensively metabolized and detected in plasma and urine . Its <font color="blue">toxicity_1</font> has previously been correlated to the <font color="blue">formation_1</font> <font color="blue">of_1</font> <font color="blue">an_1</font> <font color="blue">active_1</font> <font color="blue">metabolite_1</font> <font color="blue">,_1</font> <font color="blue">N_1</font> <font color="blue">-_1</font> <font color="blue">acetyl_1</font> <font color="blue">-_1</font> <font color="blue">amonafide_1</font> <font color="blue">._1</font> Amonafide was chosen for inclusion in the Cancer and Leukemia Group B ( CALGB ) master metastatic breast cancer protocol . CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of several Phase II agents given for up to four cycles and then followed by standard cyclophosphamide - doxorubicin-5-fluorouracil , or to immediate treatment with standard cyclophosphamide - doxorubicin-5-fluorouracil . The end point of <font color="blue">CALGB_1</font> <font color="blue">8642_1</font> is to assess the difference in <font color="blue">survival_3</font> <font color="blue">,_3</font> <font color="blue">toxicity_3</font> <font color="blue">,_3</font> <font color="blue">and_3</font> <font color="blue">overall_3</font> <font color="blue">response_3</font> <font color="blue">when_1</font> <font color="blue">limited_1</font> <font color="blue">exposure_1</font> <font color="blue">to_1</font> <font color="blue">Phase_1</font> <font color="blue">II_1</font> <font color="blue">agents_1</font> <font color="blue">precedes_1</font> <font color="blue">standard_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">._1</font> This report deals only with amonafide as a Phase II agent . Comparisons with the cyclophosphamide - doxorubicin-5-fluorouracil arm will not be addressed . Patients had to have histologically documented measurable breast cancer and a performance status of 0 - 1 . Patients could not have had prior chemotherapy for metastatic disease . Prior adjuvant chemotherapy was permitted . Patients could not have <font color="blue">visceral_1</font> <font color="blue">crisis_1</font> <font color="blue">._1</font> Amonafide was given at 300 mg / m2/day i.v . for 5 days , and repeated at 21-day intervals for a maximum of four cycles . <font color="blue">Escalation_1</font> <font color="blue">and_1</font> <font color="blue">reduction_1</font> <font color="blue">in_1</font> <font color="blue">dose_1</font> was mandated dependent on <font color="blue">hematotoxicity_2</font> or lack thereof . <font color="blue">Toxicity_5</font> <font color="blue">was_1</font> <font color="blue">primarily_1</font> <font color="blue">hematological_1</font> <font color="blue">and_1</font> <font color="blue">bimodal_1</font> <font color="blue">:_1</font> 32% had grade 3 or 4 <font color="blue">leukopenia_2</font> and 24% had grade 3 or 4 <font color="blue">thrombocytopenia_2</font> <font color="blue">;_2</font> 22% had <font color="blue">no_1</font> <font color="blue">leukopenia_2</font> and 44% had no <font color="blue">thrombocytopenia_2</font> <font color="blue">._2</font> The <font color="blue">response_2</font> <font color="blue">rate_2</font> was 18% , including one complete response . When response was analyzed by <font color="blue">hematological_2</font> <font color="blue">toxicity_2</font> <font color="blue">,_2</font> there was a 35.7% <font color="blue">response_1</font> if patients had <font color="blue">leukopenia_2</font> grade 3/4 ( versus 8.3% , P = 0.08 ) . There was a 50% <font color="blue">response_1</font> <font color="blue">if_1</font> <font color="blue">patients_1</font> <font color="blue">had_1</font> <font color="blue">thrombocytopenia_2</font> grade 3/4 ( versus 7.1% , P = < 0.01 ) . We conclude that amonafide is somewhat active in previously untreated breast cancer patients . There may be a <font color="blue">steep_2</font> <font color="blue">dose_2</font> <font color="blue">-_2</font> <font color="blue">response_2</font> <font color="blue">curve_2</font> <font color="blue">,_2</font> <font color="blue">based_1</font> <font color="blue">on_1</font> <font color="blue">the_1</font> <font color="blue">significant_1</font> <font color="blue">correlation_1</font> <font color="blue">between_1</font> <font color="blue">myelosuppression_3</font> <font color="blue">and_1</font> <font color="blue">response_1</font> <font color="blue">._1</font> <font color="blue">Rates_2</font> <font color="blue">of_2</font> <font color="blue">responses_2</font> <font color="blue">in_1</font> <font color="blue">patients_1</font> adequately dosed ( i.e. , with significant <font color="blue">hematotoxicity_1</font> <font color="blue">)_1</font> with amonafide ranged from 35 to 50% . Further studies will incorporate individualized dosing based on pretreatment acetylator phenotyping .